[1]刘敬敬,程玉峰,崔 磊.化痰止咳平喘汤联合布地奈德治疗慢性阻塞性肺疾病急性加重期临床研究[J].陕西中医,2024,(2):204-207.[doi:DOI:10.3969/j.issn.1000-7369.2024.02.012]
　LIU Jingjing,CHENG Yufeng,CUI Lei.Huatan Zhike Pingchuan decoction combined with budesonide in the treatment of acute exacerbation of COPD[J].,2024,(2):204-207.[doi:DOI:10.3969/j.issn.1000-7369.2024.02.012]
点击复制

化痰止咳平喘汤联合布地奈德治疗慢性阻塞性肺疾病急性加重期临床研究
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2024年2期
页码:
204-207
栏目:
临床研究
出版日期:
2024-02-05

文章信息/Info

Title:
Huatan Zhike Pingchuan decoction combined with budesonide in the treatment of acute exacerbation of COPD
作者:
刘敬敬; 程玉峰; 崔 磊
(亳州市中医院,安徽 亳州 236800)
Author(s):
LIU Jingjing; CHENG Yufeng; CUI Lei
(Bozhou Hospital of Traditional Chinese Medicine,Bozhou 236800,China)
关键词:
慢性阻塞性肺疾病;  急性加重期;  布地奈德;  化痰止咳平喘汤;  呼吸功能;  血气分析
Keywords:
Chronic obstructive pulmonary disease;  Acute exacerbation;  Budesonide;  Huatan Zhike Pingchuan decoction;  Respiratory function;  Blood gas analysis
分类号:
R 563
DOI:
DOI:10.3969/j.issn.1000-7369.2024.02.012
文献标志码:
A
摘要:
目的:研究化痰止咳平喘汤联合布地奈德治疗慢性阻塞性肺疾病急性加重期(COPD)的效果及作用机制。方法:选取急性加重期COPD患者94例,采用随机数字表法分为观察组及对照组各47例。对照组患者接受布地奈德联合常规方案治疗; 观察组患者在上述治疗方案的基础上联合化痰止咳平喘汤治疗; 记录并比较两组患者治疗有效率、治疗前后主要临床症状(咳嗽咳痰、气促气短、胸闷胀痛)的中医症候积分、用力肺活量(FVC)、呼气峰流量(PEF)、第一秒用力呼气容积占FVC百分比(FEV1/FVC)、二氧化碳分压(PaCO2)、血氧气分压(PaO2)、6 min步行试验距离(6MWT)以及不良反应发生率。结果:观察组治疗有效率为95.74%,显著高于对照组的82.98%(P<0.05); 治疗后,两组咳嗽咳痰、气促气短、胸闷胀痛的中医症候积分相比治疗前均下降,且观察组低于对照组(P<0.05); 两组FVC、PEF、FEV1/FVC、PaO2评分及6MWT相较治疗前均出现上升,PaCO2相比治疗前下降,且观察组变化更加显著(P<0.05); 两组不良反应发生率比较差异无统计学意义(P>0.05)。结论:化痰止咳平喘汤联合布地奈德可有效改善COPD患者临床症状、促进肺功能的改善且未增加患者的不良反应发生率。
Abstract:
Objective:To study the effect and action mechanism of Huatan Zhike Pingchuan decoction combined with budesonide in the treatment of acute exacerbation of chronic obstructive pulmonary disease(COPD).Methods:A total of 94 patients with acute exacerbation of COPD were enrolled.According to random number table method,they were divided into observation group(n=47)and control group(n=47).The control group was given budesonide combined with routine regimen,while observation group was additionally treated with Huatan Zhike Pingchuan decoction.The response rate of treatment,scores of main TCM syndromes(cough and expectoration,shortness of breath,chest swelling and pain),forced vital capacity(FVC),peak expiratory flow(PEF),forced expiratory volume in 1 second/FVC(FEV1/FVC),partial pressure of carbon dioxide(PaCO2),partial pressure of blood oxygen(PaO2),6 minute walking distance(6MWT)and incidence of adverse reactions in the two groups were compared before and after treatment.Results:The response rate of treatment in observation group was significantly higher than that in control group(P<0.05).After treatment,scores of main TCM syndromes in both groups were decreased,which were lower in observation group than control group(P<0.05).After treatment,FVC,PEF,FEV1/FVC,PaO2 and 6MWT were increased,while PaCO2 was decreased in both groups,and the above changes were more significant in observation group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Huatan Zhike Pingchuan decoction combined with budesonide can effectively improve clinical symptoms and promote the improvement of pulmonary function in COPD patients,with low incidence of adverse reactions.

参考文献/References:

[1] 周文雯,杨晓东,孙建,等.不同剂量盐酸氨溴索辅助治疗对慢性阻塞性肺疾病患者肺功能、氧化应激及免疫功能的影响[J].成都医学院学报,2019,14(6):736-740,745.
[2] 李彩娟,李建红,陈丽.伊伐布雷定对COPD伴SVT患者血流动力学和心肺功能的影响[J].川北医学院学报,2020,35(6):1017-1020.
[3] 王新梅,栾念旭,靳岱红.噻托溴铵联合布地奈德福莫特罗治疗稳定期COPD疗效及对细胞免疫功能的影响[J].中国医师杂志,2019,21(8):1254-1256.
[4] 李霄,李霖,张晗.基于《中华医典》数据挖掘的明清医案痰证用药规律研究[J].云南中医学院学报,2020,43(2):77-83.
[5] 孙婉瑾,王金波,闫斌,等.化痰止咳平喘类中药汤剂相对密度监测的数学模型研究[J].医药导报,2020,39(7):949-953.
[6] 慢性阻塞性肺疾病急性加重(AECOPD)诊治专家组.慢性阻塞性肺疾病急性加重(AECOPD)诊治中国专家共识(2017年更新版)[J].国际呼吸杂志,2017,37(14):1041-1057.
[7] 国家食品药品监督管理总局.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002:85-87.
[8] 李翔,杨旭.6分钟步行试验在心脏康复中的作用[J].中国临床医生杂志,2018,46(5):507-510.
[9] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2013年修订版)[J].中华结核和呼吸杂志,2013,36(4):255-264.
[10] 慢性阻塞性肺疾病急性加重抗菌治疗论坛专家组.“慢性阻塞性肺疾病诊治指南”中急性加重抗菌治疗的地位[J].中华结核和呼吸杂志,2013,36(9):712-714.
[11] 宋卫东,赵庆忠,蔡波,等.益气活血化痰汤、无创双水平气道正压通气联合纳美芬治疗老年慢性阻塞性肺疾病合并Ⅱ型呼吸衰竭疗效研究[J].陕西中医,2023,44(4):455-458.
[12] 杨汀.慢性阻塞性肺疾病吸入性三联药物治疗的研究进展[J].中华结核和呼吸杂志,2019,42(8):637-639.
[13] 王雅宁,米婷,周红.不同通气模式治疗慢性阻塞性肺疾病合并呼吸衰竭临床疗效及患者呼吸动力学、肺功能水平比较[J].陕西医学杂志,2023,52(1):36-39,44.
[14] 冯超.中药祛痰救肺汤联合针灸治疗预防COPD稳定期患者急性复发的价值[J].海南医学,2018,29(2):177-180.
[15] 朱传武,肖厚金.小青龙汤治疗老年慢性阻塞性肺疾病发作期临床观察[J].光明中医,2023,38(6):1078-1081.
[16] 杨真卿,王令敏,侯硕,等.武蕾教授从五脏论治慢性阻塞性肺疾病的临床经验[J].现代中西医结合杂志,2021,30(3):278-281,315.
[17] 韩云霞,葛正行,李德鑫,等.吉贝咳喘汤治疗慢性阻塞性肺病[J].中国实验方剂学杂志,2011,17(7):227-229.
[18] 鹿振辉,张惠勇,张琼,等.风叶咳喘平合剂治疗急性支气管炎咳嗽(风热犯肺)的随机双盲多中心临床研究[J].中成药,2014,36(6):1151-1155.
[19] 王振伟,沈丽,张喆,等.百部在治疗肺系统疾病中的研究进展[J].临床肺科杂志,2013,18(3):520-522.
[20] 韦宇,邵蒙苏,于同月,等.桑白皮的临床应用及其用量探究[J].吉林中医药,2021,41(4):528-531.
[21] 李奕,李伟平.鱼腥草治疗呼吸系统疾病处方分析及理论研究[J].浙江中医杂志,2023,58(5):380,385.
[22] 朱彤,江培春.败酱草古今用[J].光明中医,2015,26(3):638-640.
[23] 李竹英,陈璐,王丽洁.麻黄-白果药对“异病同治”支气管哮喘和慢性阻塞性肺疾病药理作用研究[J].陕西中医,2021,42(8):1128-1132.
[24] 唐万云,曾玉英,汪秀玲,等.益气活血方治疗慢性阻塞性肺疾病稳定期疗效及对患者肺功能、炎症因子的影响[J].陕西中医,2020,41(11):1576-1579,1583.
[25] 庞卫花,李金巍,宗广帅,等.阿奇霉素联合布地奈德对支原体肺炎患儿细胞因子、共刺激分子和免疫功能的影响[J].河北医药,2020,42(3):362-365.
[26] 康睿,刘慧霞.肺部感染控制窗序贯通气在慢性阻塞性肺疾病急性加重期合并呼吸衰竭治疗中的应用价值研究[J].陕西医学杂志,2022,51(3):342-346.

相似文献/References:

[1]杨栓柱,王 文 △,李 猛,等.千金苇茎汤合瓜蒌薤白杏仁汤治疗 慢性阻塞性肺疾病急性加重期临床研究*[J].陕西中医,2019,(5):600.
[2]王 敏,陈 阁.清热化痰祛瘀方联合西药治疗慢性阻塞性肺疾病急性 加重期患者的临床研究[J].陕西中医,2019,(5):610.
　WANG Min,CHEN Ge..Clinical study of Qingre Huatan Quyu prescription combined with western medicine in the treatment of acute exacerbation of chronic obstructive pulmonary disease[J].,2019,(2):610.
[3]李天浩,韩晨旭,王惠琴,等.基于EGFR-MUC5AC信号通路探讨参鱼化痰口服液干预慢性阻塞性肺疾病大鼠气道黏液高分泌的机制*[J].陕西中医,2019,(8):995.
　LI Tianhao,HAN Chenxu,WANG Huiqin,et al.Based on EGFR-MUC5AC signaling pathway to explore the mechanism of Shenyu Huatan oral liquid in intervention of airway mucus high secretion in COPD rats[J].,2019,(2):995.
[4]王珊珊,谭光波△.补肺汤对慢性阻塞性肺疾病肺气肿大鼠血清IFNγ、IL4表达水平影响研究*[J].陕西中医,2019,(11):1491.
　WANG Shanshan,TAN Guangbo..Effect of Bufei decoction on the expression of IFNγ and IL4 in serum of rats with chronic obstructive pulmonary disease and emphysema[J].,2019,(2):1491.
[5]任英杰,王 起,陈秋生.黄芪汤加减治疗急性加重期慢性阻塞性肺疾病疗效研究[J].陕西中医,2020,(1):57.
　REN Yingjie,WANG Qi,CHEN Qiusheng..Observation on the curative effect of Huangqi decoction in the treatment ofacute exacerbation of chronic obstructive pulmonary disease[J].,2020,(2):57.
[6]聂清华,范伏元△.射干麻黄汤联合沙丁胺醇对慢性阻塞性肺疾病患者肺功能、生活质量的影响[J].陕西中医,2020,(2):180.
　NIE Qinghua,FAN Fuyuan..Effects of Shegan Mahuang decoction and albuterol on pulmonary function and quality of life in patients with COPD[J].,2020,(2):180.
[7]刘新平,王展儒.理肺化痰通脉方治疗慢性阻塞性肺疾病急性加重期临床研究[J].陕西中医,2020,(4):484.
[8]任素霞,陶赟臻△,张美玲.益气消癥通络方联合西药对慢性阻塞性肺疾病急性加重期患者BODE指数及CRP的影响[J].陕西中医,2020,(7):920.[doi:DOI:10.3969/j.issn.10007369.2020.07.024]
[9]唐颖丽,谢 珊,余清萍,等.子午流注法治疗慢性阻塞性肺疾病加重期痰浊阻肺证疗效研究*[J].陕西中医,2020,(9):1311.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.039]
　TANG Yingli,XIE Shan,YU Qingping,et al.Curative effect of midnight-noon ebb-flow method on chronic obstructive pulmonary disease exacerbation with syndrome of Tanzhuo Zufei[J].,2020,(2):1311.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.039]
[10]蔡东林,孙钟和,赵益庆.慢性阻塞性肺疾病稳定期BODE指数、IL-8、TNF-α水平与肺肾气虚证相关性研究*[J].陕西中医,2020,(11):1573.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.015]
[11]杜沂岚,唐 敏,陈朝晖△,等.经肺腧穴中药离子导入联合振动排痰治疗慢性阻塞性肺疾病急性加重期临床疗效*[J].陕西中医,2020,(4):534.
　DU Yilan,TANG Min,CHEN Zhaohui,et al.Clinical efficacy of Chinese medicine iontophoresis via Feishu point combined with vibration sputum discarding in the treatment of AECOPD[J].,2020,(2):534.
[12]杨 诚.清肺化痰汤合桑白皮汤治疗慢性阻塞性肺疾病急性加重期痰热壅肺证疗效及对患者免疫功能的影响[J].陕西中医,2021,(9):1223.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.018]

备注/Memo

备注/Memo:
基金项目:国家中医药管理局中医药循证能力建设项目(2019XZZX-LG001)
更新日期/Last Update: 2024-02-07